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A person-time analysis of hospital activity among cancer
survivors in England
J Maddams*,1, M Utley2 and H Møller1
1King’s College London, Thames Cancer Registry, 1st Floor, Capital House, 42 Weston Street, London SE1 3QD, UK; 2Clinical Operational Research Unit,
University College London, 4 Taviton Street, London WC1H 0BT, UK
BACKGROUND: There are around 2 million cancer survivors in the UK. This study describes the inpatient and day case hospital activity
among the population of cancer survivors in England. This is one measure of the burden of cancer on the individual and the health
service.
METHODS: The national cancer registry data set for England (1990–2006) is linked to the NHS Hospital Episode Statistics (HES)
database. Cohorts of survivors were defined as those people recorded in the cancer registry data with a diagnosis of breast,
colorectal, lung or prostate cancer before 2007. The person-time of prevalence in 2006 for each cohort of survivors was calculated
according to the cancer type, sex, age and time since diagnosis. The corresponding HES episodes of care in 2006 were used to
calculate the person-time of admitted hospital care for each cohort of survivors. The average proportion of time spent in hospital by
survivors in each cohort was calculated as the summed person-time of hospital activity divided by the summed person-time of
prevalence. The analysis was conducted separately for cancer-related episodes and non-cancer-related episodes.
RESULTS: Lung cancer survivors had the highest intensity of cancer-related hospital activity. For all cancers, cancer-related hospital
activity was highest in the first year following diagnosis. Breast and prostate cancer survivors had peaks of cancer-related hospital
activity in the relatively young and relatively old age groups. The proportion of time spent in hospital for non-cancer-related care was
much lower than that for cancer-related care and increased gradually with age but was generally constant regardless of time since
diagnosis.
CONCLUSION: The person-time approach used in this study is more revealing than a simple enumeration of cancer survivors
and hospital admissions. Hospital activity among cancer survivors is highest soon after diagnosis. The effect of age on the amount of
hospital activity is different for each type of cancer.
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Cancer survivors are defined as people who are alive following
a diagnosis of cancer from some point in their past. In UK,
there are approximately 2 million cancer survivors (approxi-
mately 1.66 million of these in England), and this number is
increasing by 3% per year (Maddams et al, 2009). The size and
demographics of the population of cancer survivors has been
described, but there is still a need for more detailed analyses of the
burden of cancer on the individual and on health-service
resources.
This work presents a person-time analysis of a linked cancer
registry and health-service activity data set. ‘Person-time of
survivorship’ refers to the total time at risk of hospitalisation
experienced by a population of survivors, and ‘person-time of
hospitalisation’ refers to the total time spent in hospital by this
population. Acute health-service utilisation among cancer survi-
vors in England is described according to age and time since
diagnosis, for both cancer- and non-cancer-related care. The work
presented here is complementary to that previously published by
the same authors (Maddams et al, 2011).
MATERIALS AND METHODS
Data
The analysis was based on two linked data sets (Maddams et al,
2011). The first was a national merged cancer registry data set
featuring patient and diagnostic information relating to all cancers
recorded by the eight regional population-based cancer registries
in England. The merging process was carried out by the staff at the
Thames Cancer Registry (TCR), on behalf of the United Kingdom
Association of Cancer Registries (UKACR). This provided 100%
coverage of geographical regions of England and included all
registered cancers diagnosed from 1990 to 2006 (inclusive).
This data set was linked to an extract from the NHS Hospital
Episode Statistics (HES). Hospital Episode Statistics is a record-
level data repository managed by the National Health Service
Information Centre on behalf of the Secretary of State for Health. It
contains patient, clinical and administrative details for admitted
patients and outpatients treated in NHS hospitals in England, and
is mainly populated by extracts from routine data flows exchanged
between health-care providers and commissioners (NHS Health
and Social Care Information Centre, 2010). Each HES record*Correspondence: Dr J Maddams; E-mail: jacob.maddams@kcl.ac.uk
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defines a finished consultant episode (FCE) of care under a given
consultant in a given NHS provider. A patient’s journey from
admission to discharge may be made up of several FCEs. The
English Cancer Registries’ National HES extract is a subset of the
complete HES database and contains only episodes for admitted
patients (i.e., inpatients and day patients) who have at least one
recorded episode ‘for or with’ cancer. An episode is considered to
be ‘for or with’ cancer if any of its 14 diagnostic fields contain an
ICD-10 code between C00 and C97 (malignant neoplasms),
between D01 and D48 (in situ, benign or uncertain neoplasms)
or equal to O01 (hydatidiform mole).
The linkage between these two data sets was designed and
developed jointly by the TCR and the Northern and Yorkshire
Cancer Registry and Information Service on behalf of the UKACR.
The methodology matches fields such as sex, date of birth, date of
death, NHS number and postcode across the two data sets and
provides a unique patient identifier for matched patients. Using
the patient identifier as a link, it is possible to extract all HES
episodes of care for a cohort of cancer patients, as defined in the
national cancer registry data set.
The national cancer registry data set was used to identify a cohort
of cancer survivors who had been both diagnosed with a malignant
neoplasm (ICD-10 C00–C97 excluding C44) in the period 1990–
2006, and alive for at least some portion of 2006 (Maddams et al,
2011). Subcohorts were defined according to the type of cancer
diagnosis received: colon, rectum and anus cancers (ICD-10 C18–
C21); lung, bronchus and trachea cancers (ICD-10 C33–C34);
prostate cancer (ICD-10 C61); and female breast cancer (ICD-10
C50). Survivors with multiple diagnoses entered multiple subco-
horts. The unique patient identifiers were then used to extract all the
HES episodes of care that occurred in, or overlapped, the year 2006
for the cohorts of cancer survivors. As the English Cancer Registries’
HES extract contains all inpatient and day case episodes for those
patients with at least one cancer-related episode in the entire HES
data set, the extracted cancer survivor episodes may or may not
mention cancer. Episodes not mentioning cancer may have
pertained to an entirely unrelated condition, or (less likely) may
have been incorrectly coded. Some cancer survivors had no
matching HES episode of care in 2006, because of a failure to
register episodes that did occur, a failure in the matching procedure
between the two data sets or simply because they were not admitted
to hospital in 2006. In this analysis, matched episodes of care were
considered to be ‘cancer related’ if one of the 14 diagnostic codes
was between C00 and C97 (excluding C44); otherwise, they were
considered to be ‘non-cancer related’.
Hospital activity among cancer survivors
A person-time approach was used to describe the effect of age and
time since diagnosis on the amount of hospital activity in the
population of cancer survivors. When considering the interaction
of survivors with the health service, a person-time approach has a
distinct advantage, as it allows us to estimate the proportion of
survivor time spent admitted to hospital, as well as to count the
number of admissions. The calendar year 2006 was the period of
analysis. The effect of age was analysed in 5-year age groups, and
the effect of time since diagnosis was analysed in 1-year periods
and broader periods (o1, 1–5 and 5–16 years since diagnosis).
Diagnoses were available for the period 1990–2006, and thus
there were some survivors in the 2006 cohort who had been
diagnosed more than 16 years (but less than 17 years) previously.
However, the cohort did not contain all such survivors (as no
diagnoses from 1989 were available), and therefore the maximum
time since diagnosis considered was 16 years.
For each survivor in each cohort, the person-time for which they
were prevalent in 2006 (i.e., that which was postdiagnosis and
predeath and overlapped the calendar year 2006) was split into
segments according to the time points at which the indexing
variables ‘time since diagnosis’ and ‘age’ changed (Maddams et al,
2011). The amount of time spent in hospital by cancer survivors
was counted in a similar way, according to age and time since
diagnosis, for cancer-related and non-cancer-related episodes of
care separately. This was achieved using the SAS software package
(SAS Institute Inc., Cary, NC, USA) and code developed by
JM specifically for this task, similar to the program Lexis.sas by
Carstensen (2007).
The proportion of person-time each cohort of survivors spent
admitted to hospital, according to age and time since diagnosis,
was then calculated by dividing the total population person-time
spent in HES activity by the total population person-time
of prevalence. This quantity may be interpreted as the mean
proportion of time spent in HES activity by a survivor of a given
age and time since diagnosis sampled at random. An alternative
interpretation is that the quantity provides an estimate of the
probability of that survivor being an admitted hospital patient on
any given day in the period. It may be presented either as the
number of days spent admitted to hospital per 100 person-days or
as a percentage of time. Confidence intervals (CIs) for this
proportion were calculated by using a standard binomial model,
modified to include a dependence parameter (Klotz, 1973;
Budescu, 1985), to account for the fact that days spent in hospital
for an individual survivor are likely to be clustered together in
episodes or spells of care, rather than randomly distributed in
time. The dependence was assumed to be of the first-order Markov
type, and both the dependence parameters and CIs were estimated
using the methods described in Budescu (1985).
RESULTS
Tables 1 and 2, and the corresponding Figures 1 and 2, display the
average number of days (per 100 person-days) that cancer
survivors spent admitted to hospital in England during 2006, by
5-year age group or 1-year time since diagnosis period. Data are
presented for cancer-related and non-cancer-related episodes of
care separately, but are omitted if less than 20 person-years of
survivorship contributed to the estimate.
In all age groups older than 35 years, the number of days
admitted to hospital for cancer-related episodes of care (per 100
person-days) was highest among lung cancer survivors; it was
lowest among prostate and breast cancer survivors. Among
prostate cancer survivors, the relatively young and relatively old
age groups spent a higher number of days admitted to hospital for
cancer-related episodes (per 100 person-days) than the middle-age
groups (55–75 years). A similar trend was observed among breast
cancer survivors, although the observed increase in the number of
days spent admitted to hospital above the age of 75 years was not
as significant as among prostate cancer survivors. Among male
lung and colorectal cancer survivors, the number of days spent
admitted to hospital for cancer-related episodes of care (per 100
person-days) generally decreased as age increased – this associa-
tion was reversed in male lung cancer survivors under the age of 50
years, but CIs were wide because of a relatively small number of
lung cancer survivors in these age groups. Similar age effects were
observed among female lung and colorectal cancer survivors.
The number of days spent admitted to hospital for non-cancer-
related episodes of care (per 100 person-days) generally increased
as age increased above 60 years. Colorectal and lung cancer
survivors spent a similar number of days admitted for non-cancer-
related episodes of care (per 100 person-days); however, prostate
and breast cancer survivors spent significantly fewer.
The number of days survivors spent admitted to hospital (per
100 person-days) for cancer-related episodes of care was much
higher in the first year following diagnosis than at any other time.
In the first 5 years after diagnosis, it was highest among survivors
of lung cancer.
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Three periods of time after diagnosis were considered in detail:
o1 year, between 1 and 5 years and 5–16 years (as only diagnoses
from 1990–2006 were available). The first period contained the
majority of the cancer-related hospital activity for all cancer
survivors, but the period between 1 and 5 years after diagnosis also
had a significant amount of hospital activity.
Figure 3 displays the average number of days spent admitted to
hospital (per 100 person-days) by cancer survivors in England in
2006, by 5-year age group and broad post-diagnosis period. Only
cancer-related episodes of care are presented in this figure. As with
all tables and figures, data are omitted if less than 20 person-years of
survivorship contributed. Figure 3 shows that, for each age group,
the number of days spent admitted to hospital for cancer-related
episodes of care (per 100 person-days) was highest in the first year
after diagnosis. For colorectal cancer survivors, it was approxi-
mately 30 times higher than in the period45 years after diagnosis.
Similarly, for lung cancer survivors, it was approximately 35 times
higher than in the period45 years after diagnosis. The period 1–5
years after diagnosis also contained significantly more cancer-
related hospital activity than the period45 years after diagnosis: it
was approximately four times higher among colorectal cancer
survivors, and 7 times higher among lung cancer survivors,
although Figure 2 shows that much of this increase is due to the
high activity in years 2 and 3 after diagnosis. There was a smaller
difference in the cancer-related activity in the periods 1–5 and 45
years after diagnosis among prostate and female breast cancer
survivors, compared with colorectal and lung cancer survivors.
The number of days spent admitted to hospital for cancer-
related episodes of care (per 100 person-days) in the first year after
diagnosis was significantly higher among survivors over the age of
75 years, compared with younger survivors. This is most notice-
able for survivors of prostate cancer – those agedX85 years spent
around three times as many days admitted in the first year after
diagnosis, compared with those aged 70–74 years.
Table 1 Mean admitted patient hospital activity (cancer related and non-cancer related) among cancer survivors, England, 2006. Number of days in
hospital per 100 person-days,z by 5-year age group
Cancer diagnosis
Colon, rectum and anus Lung, bronchus and trachea Breast Prostate
Cancer
related
Non-cancer
related
Cancer
related
Non-cancer
related
Cancer
related
Non-cancer
related
Cancer
related
Non-cancer
related
Males
Age group (in years)
0–4
5–9
10–14
15–19
20–24 3.4 (2.5–4.2) 1.0 (0.5–1.5)
25–29 3.2 (2.6–3.8) 0.9 (0.7–1.2) 2.3 (0.8–3.9) 0.4 (0.0–0.9)
30–34 2.4 (2.0–2.9) 0.3 (0.2–0.5) 2.0 (1.1–2.9) 0.1 (0.0–0.3)
35–39 2.5 (2.2–2.8) 0.5 (0.4–0.6) 3.6 (2.9–4.3) 0.4 (0.0–0.7)
40–44 2.0 (1.8–2.2) 0.5 (0.4–0.5) 3.9 (3.5–4.4) 0.3 (0.1–0.5) 1.8 (1.2–2.4) 0.2 (0.0–0.5)
45–49 2.1 (2.0–2.2) 0.6 (0.6–0.7) 4.6 (4.3–5.0) 0.4 (0.3–0.6) 1.2 (0.9–1.4) 0.2 (0.1–0.3)
50–54 2.2 (2.1–2.3) 0.5 (0.5–0.6) 4.4 (4.2–4.6) 0.6 (0.5–0.7) 0.9 (0.8–1.0) 0.2 (0.2–0.3)
55–59 2.1 (2.0–2.2) 0.5 (0.5–0.6) 4.7 (4.5–4.8) 0.6 (0.5–0.7) 0.6 (0.6–0.7) 0.2 (0.2–0.2)
60–64 1.9 (1.9–2.0) 0.7 (0.6–0.7) 4.2 (4.0–4.3) 0.7 (0.6–0.8) 0.6 (0.6–0.7) 0.3 (0.3–0.3)
65–69 2.0 (1.9–2.0) 0.7 (0.7–0.7) 4.1 (4.0–4.2) 0.6 (0.6–0.7) 0.6 (0.6–0.7) 0.3 (0.3–0.3)
70–74 1.7 (1.7–1.8) 0.8 (0.8–0.9) 4.0 (3.9–4.1) 0.7 (0.7–0.8) 0.7 (0.7–0.7) 0.4 (0.4–0.4)
75–79 1.7 (1.6–1.7) 0.9 (0.9–1.0) 4.0 (3.9–4.1) 0.8 (0.7–0.8) 0.9 (0.9–0.9) 0.5 (0.5–0.6)
80–84 1.6 (1.5–1.6) 1.2 (1.2–1.2) 3.7 (3.5–3.8) 0.9 (0.9–1.0) 1.2 (1.2–1.2) 0.8 (0.8–0.8)
X85 1.4 (1.3–1.5) 1.4 (1.3–1.4) 3.2 (3.0–3.4) 0.7 (0.6–0.8) 1.7 (1.6–1.7) 1.1 (1.1–1.1)
Females
Age group (in years)
0–4
5–9
10–14
15–19 1.4 (0.1–2.6) 0.2 (0.0–0.5)
20–24 3.3 (2.3–4.2) 0.6 (0.3–0.9) 1.7 (1.1–2.3) 0.6 (0.2–1.0)
25–29 2.8 (2.2–3.4) 0.5 (0.3–0.7) 2.0 (0.0–4.7) 0.2 (0.0–0.8) 2.1 (2.0–2.4) 0.3 (0.1–0.4)
30–34 2.1 (1.6–2.5) 0.5 (0.4–0.7) 1.5 (0.6–2.5) 0.2 (0.0–0.5) 1.6 (1.5–1.7) 0.3 (0.2–0.4)
35–39 2.5 (2.2–2.8) 0.6 (0.5–0.7) 3.1 (2.4–3.7) 0.3 (0.1–0.5) 1.3 (1.2–1.3) 0.3 (0.2–0.3)
40–44 2.3 (2.1–2.5) 0.5 (0.4–0.6) 3.3 (2.9–3.6) 0.4 (0.2–0.6) 1.0 (0.9–1.0) 0.3 (0.2–0.3)
45–49 2.2 (2.0–2.3) 0.6 (0.5–0.7) 3.9 (3.6–4.2) 0.5 (0.4–0.7) 0.8 (0.8–0.8) 0.2 (0.2–0.2)
50–54 2.0 (1.9–2.1) 0.5 (0.4–0.5) 4.2 (4.0–4.4) 0.5 (0.4–0.6) 0.6 (0.6–0.6) 0.2 (0.2–0.3)
55–59 1.8 (1.7–1.9) 0.5 (0.5–0.5) 4.3 (4.2–4.5) 0.4 (0.4–0.5) 0.5 (0.5–0.5) 0.2 (0.2–0.2)
60–64 1.7 (1.6–1.8) 0.5 (0.4–0.5) 4.2 (4.1–4.4) 0.5 (0.5–0.6) 0.5 (0.4–0.5) 0.2 (0.2–0.2)
65–69 1.6 (1.6–1.7) 0.6 (0.5–0.6) 4.0 (3.9–4.1) 0.6 (0.5–0.6) 0.5 (0.5–0.5) 0.3 (0.3–0.3)
70–74 1.6 (1.5–1.7) 0.7 (0.7–0.7) 4.1 (4.0–4.3) 0.7 (0.7–0.8) 0.5 (0.5–0.5) 0.4 (0.4–0.4)
75–79 1.5 (1.5–1.6) 0.8 (0.8–0.9) 3.9 (3.8–4.1) 0.9 (0.9–1.0) 0.6 (0.6–0.6) 0.6 (0.6–0.6)
80–84 1.5 (1.4–1.5) 1.2 (1.1–1.2) 4.3 (4.2–4.6) 1.0 (0.9–1.1) 0.7 (0.6–0.7) 0.9 (0.9–0.9)
X85 1.1 (1.1–1.2) 1.3 (1.2–1.3) 3.8 (3.5–4.1) 0.9 (0.8–1.0) 0.8 (0.8–0.8) 1.2 (1.2–1.2)
zWith 95% confidence intervals. Only observations with at least 20 survivor person-years are included.
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DISCUSSION
This paper presents a person-time analysis of a linked cancer
registry and hospital activity data set for England. Age and time
since diagnosis were anticipated to be important factors in the
level of health-care utilisation among cancer survivors, and were
studied in detail. The linked data sets allowed an analysis of all
recorded episodes of hospital inpatient or day case health care in
England during 2006 among registered cancer survivors, with at
least one cancer-related episode recorded in the HES in the period
1990–2006. A person-time approach was used throughout, which
made it possible to quantify the intensity of hospitalisation, as well
as the associated burden on cancer survivors and the health
service, by considering the amount of time spent in hospital, rather
than just the number of admissions. Person-time of survivorship
and person-time of hospitalisation were classified according to the
variables of interest (age and time since diagnosis) – this made it
possible to describe in detail the ways in which acute health-service
utilisation among survivors was related to these factors.
It is not possible to distinguish between the cancer survivors
who had no recorded hospital activity and those for whom the
linkage process between the cancer registry and HES data failed.
It was therefore not possible to exclude patients with ‘no match’ to
HES. This results in an underestimation of the amount of hospital
activity among the cancer survivors, but this is believed to be only
a small effect.
Each record in the HES data had up to 14 diagnostic codes
(using the ICD-10 classification), and 12 operation procedure
codes (using the OPCS4 classification), with the first of each of
these codes intended to indicate the primary diagnosis/intent
of the episode (Maddams et al, 2011). For simplicity, episodes of
care were broadly categorised as ‘related to cancer’ or ‘not related
to cancer’ according to the diagnostic codes only – an episode was
considered to be cancer related if any of the diagnostic codes was
between C00 and C97 (excluding C44). This was an intentionally
broad definition, designed to negate any possible regional
variation in coding of primary diagnosis in the HES data, and to
take account of the wide range of health problems associated with
cancer and the side effects of its treatment. Defined thus, ‘cancer-
related’ hospitalisation for a given survivor may be considered as
that directly or indirectly caused by, or associated with, a cancer
diagnosis. A future area of study may be to define ‘cancer-related’
HES admissions according to the clinical procedure codes, as well
as the admission codes.
Table 2 Mean admitted patient hospital activity (cancer related and non-cancer related) among cancer survivors, England, 2006. Number of days in
hospital per 100 person-days,z by time since diagnosis
Cancer diagnosis
Colon, rectum and anus Lung, bronchus and trachea Breast Prostate
Cancer
related
Non-cancer
related
Cancer
related
Non-cancer
related
Cancer
related
Non-cancer
related
Cancer
related
Non-cancer
related
Males
Years since diagnosis
o1 7.7 (7.7–7.8) 1.3 (1.3–1.4) 9.7 (9.6–9.7) 1.0 (1.0–1.1) 1.8 (1.8–1.9) 0.5 (0.5–0.5)
1–2 1.5 (1.4–1.5) 1.0 (1.0–1.1) 3.0 (2.9–3.1) 0.6 (0.5–0.7) 0.8 (0.8–0.9) 0.4 (0.4–0.5)
2–3 1.0 (1.0–1.1) 0.9 (0.9–0.9) 1.7 (1.5–1.8) 0.7 (0.7–0.8) 0.7 (0.7–0.8) 0.5 (0.5–0.5)
3–4 0.8 (0.8–0.9) 0.9 (0.8–0.9) 1.0 (0.9–1.2) 0.6 (0.5–0.7) 0.7 (0.7–0.8) 0.5 (0.5–0.6)
4–5 0.6 (0.6–0.7) 0.9 (0.8–0.9) 0.7 (0.6–0.9) 0.7 (0.6–0.8) 0.7 (0.7–0.8) 0.5 (0.5–0.6)
5–6 0.5 (0.4–0.6) 1.0 (0.9–1.0) 0.5 (0.3–0.7) 0.7 (0.6–0.8) 0.7 (0.7–0.8) 0.6 (0.6–0.7)
6–7 0.4 (0.4–0.5) 0.9 (0.9–1.0) 0.5 (0.3–0.7) 0.8 (0.6–0.9) 0.7 (0.7–0.8) 0.6 (0.6–0.7)
7–8 0.4 (0.3–0.4) 0.9 (0.9–1.0) 0.4 (0.2–0.7) 0.7 (0.5–0.8) 0.8 (0.8–0.9) 0.6 (0.6–0.7)
8–9 0.3 (0.2–0.4) 0.8 (0.7–0.9) 0.3 (0.1–0.5) 0.7 (0.6–0.8) 0.8 (0.7–0.8) 0.8 (0.7–0.8)
9–10 0.2 (0.2–0.3) 0.6 (0.6–0.7) 0.2 (0.0–0.4) 0.4 (0.3–0.5) 0.8 (0.8–0.9) 0.6 (0.6–0.7)
10–11 0.3 (0.2–0.4) 0.6 (0.5–0.6) 0.3 (0.1–0.5) 0.2 (0.1–0.3) 0.8 (0.7–0.9) 0.6 (0.6–0.7)
11–12 0.3 (0.2–0.4) 0.5 (0.5–0.6) 0.2 (0.0–0.4) 0.3 (0.2–0.5) 0.8 (0.7–0.9) 0.6 (0.5–0.7)
12–13 0.2 (0.1–0.3) 0.4 (0.3–0.5) 0.2 (0.0–0.4) 0.2 (0.1–0.4) 0.7 (0.6–0.8) 0.5 (0.5–0.6)
13–14 0.3 (0.2–0.4) 0.4 (0.3–0.5) 0.1 (0.0–0.3) 0.2 (0.0–0.4) 0.7 (0.6–0.9) 0.5 (0.4–0.6)
14–15 0.2 (0.1–0.3) 0.4 (0.3–0.5) 0.2 (0.0–0.4) 0.3 (0.1–0.5) 0.6 (0.5–0.8) 0.5 (0.4–0.7)
15–16 0.2 (0.1–0.4) 0.5 (0.4–0.6) 0.2 (0.0–0.5) 0.1 (0.0–0.3) 0.6 (0.4–0.8) 0.5 (0.4–0.6)
Females
Years since diagnosis
o1 7.8 (7.7–7.9) 1.3 (1.3–1.4) 9.7 (9.6–9.8) 1.0 (0.9–1.0) 2.6 (2.5–2.6) 0.5 (0.5–0.5)
1–2 1.3 (1.3–1.4) 1.0 (1.0–1.0) 2.7 (2.6–2.9) 0.6 (0.6–0.7) 0.6 (0.5–0.6) 0.5 (0.5–0.5)
2–3 0.9 (0.8–0.9) 1.0 (0.9–1.0) 1.7 (1.5–1.8) 0.6 (0.5–0.7) 0.5 (0.4–0.5) 0.5 (0.5–0.5)
3–4 0.7 (0.6–0.8) 0.8 (0.8–0.9) 1.1 (0.9–1.3) 0.6 (0.5–0.8) 0.4 (0.4–0.5) 0.5 (0.5–0.5)
4–5 0.5 (0.4–0.6) 0.8 (0.8–0.9) 0.7 (0.5–0.9) 0.8 (0.7–1.0) 0.4 (0.4–0.4) 0.5 (0.5–0.5)
5–6 0.4 (0.3–0.5) 0.9 (0.9–0.9) 0.8 (0.5–1.1) 0.7 (0.6–0.8) 0.3 (0.3–0.4) 0.5 (0.5–0.5)
6–7 0.3 (0.2–0.4) 0.9 (0.8–0.9) 0.3 (0.1–0.6) 0.7 (0.5–0.9) 0.3 (0.3–0.4) 0.5 (0.5–0.6)
7–8 0.2 (0.1–0.3) 0.9 (0.9–1.0) 0.3 (0.1–0.5) 1.1 (0.9–1.3) 0.3 (0.3–0.4) 0.5 (0.5–0.5)
8–9 0.3 (0.2–0.4) 1.0 (1.0–1.1) 0.3 (0.0–0.6) 0.5 (0.3–0.7) 0.3 (0.3–0.3) 0.5 (0.4–0.5)
9–10 0.2 (0.1–0.3) 0.6 (0.6–0.7) 0.2 (0.0–0.5) 0.5 (0.3–0.8) 0.3 (0.3–0.3) 0.3 (0.3–0.3)
10–11 0.2 (0.1–0.3) 0.4 (0.4–0.5) 0.2 (0.0–0.4) 0.2 (0.0–0.4) 0.3 (0.2–0.3) 0.2 (0.2–0.2)
11–12 0.2 (0.1–0.3) 0.3 (0.3–0.4) 0.3 (0.0–0.6) 0.1 (0.0–0.3) 0.3 (0.2–0.3) 0.2 (0.2–0.3)
12–13 0.2 (0.1–0.3) 0.3 (0.3–0.4) 0.3 (0.0–0.7) 0.3 (0.1–0.5) 0.3 (0.2–0.3) 0.2 (0.2–0.2)
13–14 0.2 (0.1–0.3) 0.3 (0.3–0.4) 0.2 (0.0–0.4) 0.1 (0.0–0.3) 0.3 (0.3–0.4) 0.2 (0.2–0.3)
14–15 0.1 (0.0–0.2) 0.4 (0.3–0.4) 0.2 (0.0–0.7) 0.1 (0.0–0.3) 0.2 (0.2–0.3) 0.2 (0.2–0.3)
15–16 0.1 (0.0–0.3) 0.3 (0.2–0.4) 0.2 (0.0–0.5) 0.1 (0.0–0.4) 0.3 (0.2–0.3) 0.2 (0.2–0.3)
zWith 95% confidence intervals.
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Perhaps a more precise way of defining the health-care burden
directly attributable to cancer would be to compare hospitalisation
of any kind among cancer survivors with that observed in a
randomly selected age- and sex-matched subset of the cancer-free
population (or, more practically, the general population). This
would allow some measure of the ‘background’ hospitalisation
experienced by the cancer-free or general population to be
removed from the levels observed in cancer survivors. However,
no such data set was available to the authors at the time of analysis
– the Cancer Registries’ National HES extract only contains
episodes of care for patients with at least one episode ‘for or
with cancer’ – and thus it was only possible to make the broad
cancer/non-cancer-related distinction at a population level. It is
acknowledged, however, that at an individual level it may not be
possible to make such a clear distinction between cancer-related
and non-cancer-related health-service utilisation. Non-cancer-
related acute health-care utilisation was shown to generally
increase with age, but remained roughly constant regardless of
time since diagnosis, indicating that it may be a good minimum
measure of ‘background’ acute health-care utilisation. That said,
there is higher non-cancer-related acute health-care utilisation in
the first year following diagnosis, particularly among those with
lung and colorectal cancer. This may be explained by the fact that
some survivors may have had an emergency admission to hospital
during which they were diagnosed with cancer. In addition, some
genuine cancer-related hospital activity may not be coded as such
in the HES.
The primary motivation for using a person-time approach in
this analysis was the need to properly account for the length of
time cancer survivors spent ‘at risk’ of hospitalisation during
the period of analysis, and how this depended on both age and
time since diagnosis. The person-time methods allowed a precise
assessment of the influence of these variables on the amount of
hospitalisation among cancer survivors. The number of days
survivors spent admitted to hospital (per 100 person-days)
provides a more revealing assessment of the burden of cancer on
the health service than a count of the number of admissions.
However, the limitation of this approach is that, as person-time
is pooled for all survivors in the population, it provides only a
measure of the mean health-service utilisation in the population of
survivors and obscures the underlying distribution. For example,
on average male survivors of colorectal cancer who were no more
than 1 year from diagnosis in 2006 spent 9 days per 100 person-
days admitted to hospital (equivalent to approximately one month
per year); however, in reality, many such survivors spent no time
admitted to hospital at all, whereas others spent more than 9 days
per 100 as an admitted hospital patient. This variation in the
intensity of hospitalisation across survivors of a similar age and
post-diagnosis period is considered in Maddams et al (2011),
which used a population person-time analysis to estimate the
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proportion of survivors with a low or high level of health-service
utilisation, as well as those with none. It was shown that the
underlying distribution of hospital activity is skewed towards
those with no hospital activity, particularly in the period more
than 1 year after diagnosis, and it should therefore be kept in mind
that the mean number of days spent in hospital per 100 person
days, as described in this paper, is largely influenced by the small
number of survivors who have a very high level of hospital activity.
Another limitation of this approach when used to assess
the burden of cancer on the health service is that each day of
hospitalisation is treated equally and the variation in the burden
presented by different types of admission and procedures is not
taken into account. For example, some survivors will be admitted
to hospital for routine observation and monitoring, whereas others
will be admitted for complicated operations that consume large
amounts of hospital resources and require intense periods of
rehabilitation.
The majority of cancer-related health-service utilisation
occurred during the first year following diagnosis, for all types
of cancer studied. Most cancer patients receive some form of care
or treatment as soon as possible after diagnosis, and thus it is
perhaps unsurprising that this period contains a large amount of
hospital activity. However, this study also shows that there is a
significant amount of cancer-related health-service utilisation in
the period 1–5 years after diagnosis, particularly among survivors
of lung and colorectal cancers. This is no longer the initial
treatment phase, but is indicative of the ongoing needs of cancer
survivors.
The highest levels of cancer-related acute health-service utilisa-
tion were observed in survivors of the relatively poor prognosis
cancers, but these differences largely disappeared more than
5 years after diagnosis. This indicates that the worse prognosis
cancers required more intensive treatment regimes (including end-
of-life care) in the short to medium term after diagnosis, but not in
the long term.
Prostate cancer survivors, despite having lower levels of cancer-
related acute health-service utilisation in the first year after
diagnosis than those with colorectal, lung or breast cancer, actually
had the highest levels five or more years after diagnosis (Figure 2).
This effect is the result of the relatively high levels of hospitalisa-
tion among prostate cancer survivors aged over 70 years and five
or more years from diagnosis (Figure 3). A more detailed
investigation (not included here) showed that these survivors
experienced a large amount of hospital activity recorded in the
HES data with a non-cancer primary diagnosis code, but with
prostate cancer recorded as one of the supplementary diagnoses,
and it was largely these episodes that resulted in the relatively high
number of days spent admitted to hospital (per 100 person-days)
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among this group, compared with equivalent survivors of other
cancers. In the analysis, these episodes were considered to be
‘cancer related’ because cancer was recorded as one of the
supplementary diagnosis codes in the HES data. However, the
recorded primary diagnosis codes, together with the operation
procedure codes, indicate that these episodes were not generally
related directly to prostate cancer. For example, the most common
procedure codes were endoscopic examinations of the bladder and
urethral catheterisations of the bladder, and the most common
primary diagnosis codes were for disorders of the urinary system.
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There are several physiological changes that occur in men as they
get older and lead to alterations in lower urinary tract function,
making urinary disorders in elderly men common (Dubeau, 2006;
Griebling, 2008). Many prostate cancer survivors are likely to be
closely monitored in urology clinics for many years after initial
diagnosis – often an extended period of either ‘active surveillance’
or ‘watchful waiting’ is pursued, especially if the cancer is less
aggressive and treatment is not immediately necessary (Cancer
Research UK, 2010a). This may explain the greater hospital activity
recorded among prostate cancer survivors over the age of 70 years
many years after diagnosis, compared with male lung or colorectal
cancer survivors – it is possible that the increased observation and
monitoring of these survivors leads to a high level of urological
intervention, which is only indirectly related to their prostate
cancer diagnosis.
The patterns of cancer-related health-service utilisation by age,
as described in Figure 1, must be viewed in the context of the
findings presented in Figure 3. For example, older cancer survivors
are more likely to be more than 1 year from diagnosis, compared
with younger survivors, and this alone explains the apparent
decreasing levels of utilisation as age increases among lung and
colorectal cancer survivors. Acute health-service utilisation in the
first year after diagnosis was generally highest in survivors
aged over 70 years. Initial cancer treatment can be physically very
arduous, particularly for older patients who may be more frail and
suffering from comorbidities, resulting in more frequent and
extended admissions to hospital. Particularly striking was the
threefold increase in cancer-related acute health-service utilisation
in the first year after diagnosis among prostate cancer survivors
agedX85 years compared with those aged 65–69 years (Figure 3).
Similar, but not as significant, increases were observed among
survivors of colorectal, lung and breast cancers. Since the early
1990s, the PSA test has increasingly been available (usually to men
aged over 50 years of age) as a screening tool for prostate cancer,
although in the UK no organised PSA screening programme is in
place. This test is still controversial and considered to potentially
result in overdiagnosis and overtreatment of prostate cancers that
would otherwise never have become symptomatic (Barry, 2009;
van Leeuwen et al, 2010). Recorded incidence and survival
have, accordingly, greatly increased since the test’s introduction
(Evans and Møller, 2003; Cancer Research UK, 2010b, c), as have
the number of prostate cancer survivors (Maddams et al, 2009).
Men diagnosed with prostate cancer over the age of 70 years are
more likely to have symptomatic disease requiring intensive initial
treatment compared with those aged 50–70 years who are more
likely to have been diagnosed via the PSA test. Similarly, the
observed lower acute health-service utilisation in recently diag-
nosed breast cancer survivors aged 50–70 years (the age range
in which women are routinely invited to attend breast screening
units in England (NHS Breast Cancer Screening Programme, 2011),
compared with other age groups, reflects some of the benefits of
early detection offered by the screening programmes.
This paper highlights the significant effect that time since
diagnosis has on the average amount of hospitalisation experi-
enced by cancer survivors. The majority of cancer-related admitted
hospital episodes of care occurred in the first year following
diagnosis (when initial cancer treatment takes place); however,
there was also a significant amount of hospital activity in the
period 1–5 years after diagnosis, particularly among survivors of
colorectal and lung cancers, which is indicative of the ongoing
consequences of cancer and its treatment. Other work has shown
that the final year before death also contains significant amounts
of hospitalisation of cancer survivors (Maddams et al, 2011). These
findings help to understand the burden of cancer on the health
service, but further work is still required to identify potential areas
of unmet needs among cancer survivors.
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